Cost-Effectiveness Analysis of Option B+ for HIV Prevention and Treatment of Mothers and Children in Malawi
Authors:
Open Access
- 12 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e57778
Abstract
The Ministry of Health in Malawi is implementing a pragmatic and innovative approach for the management of all HIV-infected pregnant women, termed Option B+, which consists of providing life-long antiretroviral treatment, regardless of their CD4 count or clinical stage. Our objective was to determine if Option B+ represents a cost-effective option. A decision model simulates the disease progression of a cohort of HIV-infected pregnant women receiving prophylaxis and antiretroviral therapy, and estimates the number of paediatric infections averted and maternal life years gained over a ten-year time horizon. We assess the cost-effectiveness from the Ministry of Health perspective while taking into account the practical realities of implementing ART services in Malawi. If implemented as recommended by the World Health Organization, options A, B and B+ are equivalent in preventing new infant infections, yielding cost effectiveness ratios between US$ 37 and US$ 69 per disability adjusted life year averted in children. However, when the three options are compared to the current practice, the provision of antiretroviral therapy to all mothers (Option B+) not only prevents infant infections, but also improves the ten-year survival in mothers more than four-fold. This translates into saving more than 250,000 maternal life years, as compared to mothers receiving only Option A or B, with savings of 153,000 and 172,000 life years respectively. Option B+ also yields favourable incremental cost effectiveness ratios (ICER) of US$ 455 per life year gained over the current practice. In Malawi, Option B+ represents a favorable policy option from a cost-effectiveness perspective to prevent future infant infections, save mothers' lives and reduce orphanhood. Although Option B+ would require more financial resources initially, it would save societal resources in the long-term and represents a strategic option to simplify and integrate HIV services into maternal, newborn and child health programmes.Keywords
This publication has 35 references indexed in Scilit:
- Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approachThe Lancet, 2011
- Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trialThe Lancet Infectious Diseases, 2011
- Cost-Effectiveness of Using HAART in Prevention of Mother-To-Child Transmission in the DREAM-Project MalawiJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- What will it take to stop maternal deaths?The Lancet, 2009
- HIV antiretroviral treatment: early versus later.2005
- Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapyAIDS, 2003
- Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysisHealth Policy and Planning, 2001
- Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Meeting the NICE Requirements: A Markov Model ApproachValue in Health, 2000
- The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.1998